BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Public ClinicalTrials.gov record NCT07193511. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4/Trop2 ADC, as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a monotherapy and in combination therapy to patients with locally advanced or metastatic urothelial cancer or other solid tumors.
Study identification
- NCT ID
- NCT07193511
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 355 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 1, 2025
- Primary completion
- Feb 28, 2030
- Completion
- Aug 31, 2030
- Last update posted
- Aug 24, 2026
2025 – 2030
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Avenzo Therapeutics Recruiting Site | San Francisco | California | 94158 | Recruiting |
| Avenzo Therapeutics Recruiting Site | Aurora | Colorado | 80045 | Recruiting |
| Avenzo Therapeutics Recruiting Site | New Haven | Connecticut | 06519 | Recruiting |
| Avenzo Therapeutics Recruiting Site | Orlando | Florida | 32827 | Recruiting |
| Avenzo Therapeutics Recruiting Site | Tampa | Florida | 33612 | Recruiting |
| Avenzo Therapeutics Recruiting Site | Boston | Massachusetts | 02114 | Recruiting |
| Avenzo Therapeutics Recruiting Site | New York | New York | 10065 | Recruiting |
| Avenzo Therapeutics Recruiting Site | Chapel Hill | North Carolina | 27514 | Recruiting |
| Avenzo Therapeutics Recruiting Site | Cleveland | Ohio | 44106 | Recruiting |
| Avenzo Therapeutics Recruiting Site | Myrtle Beach | South Carolina | 29572 | Recruiting |
| Avenzo Therapeutics Recruiting Site | Nashville | Tennessee | 37203 | Recruiting |
| Avenzo Therapeutics Recruiting Site | Austin | Texas | 78758 | Recruiting |
| Avenzo Therapeutics Recruiting Site | Houston | Texas | 77030 | Recruiting |
| Avenzo Therapeutics Recruiting Site | Irving | Texas | 75039 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07193511, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 24, 2026 · Synced Sep 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07193511 live on ClinicalTrials.gov.